Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

v3.24.1.u1
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 06, 2021
Jan. 31, 2022
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs     $ 15,000,000 $ 9,600,000  
Contingent consideration under RPAs, AAAs and CPPAs     3,000,000   $ 7,000,000
Receipts under RPAs, AAAs and CPPAs     7,771,000 $ 2,366,000  
Short-term royalty and commercial payment receivables     9,819,000   $ 14,215,000
Affitech          
Agreements          
Reduction in short-term royalty receivable balance due to receipt of payment     7,396,000    
Recognition of contingent consideration, Short-Term     3,000,000    
Affitech | Commercial Payment Purchase Agreement          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs $ 6,000,000.0   6,000,000.0    
Period from each royalty payment date payment is due         60 days
Maximum regulatory and commercial sales milestone payments 20,000,000.0        
Acquisition of royalty and commercial payment receivables, Long-Term 14,000,000.0        
Maximum commercial sales milestone payments $ 12,000,000.0   3,000,000.0    
Receipts under RPAs, AAAs and CPPAs     7,400,000    
Short-term royalty and commercial payment receivables     7,800,000   $ 12,200,000
Recognition of contingent consideration, Short-Term     3,000,000.0    
Recognition of contingent consideration, Long-Term         6,000,000.0
Amount of allowance for credit losses     0   0
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO)          
Agreements          
Payments eligible to receive (as a percent) 0.50%        
Commercial payment receivable term 10 years        
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO) | United States          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs   $ 5,000,000.0      
Affitech | Commercial Payment Purchase Agreement | Faricimab (VABYSMO) | Europe          
Agreements          
Payments of consideration under RPAs, AAAs and CPPAs   $ 3,000,000.0      
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones          
Agreements          
Contingent consideration under RPAs, AAAs and CPPAs $ 8,000,000.0        
Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, first and second          
Agreements          
Contingent consideration under RPAs, AAAs and CPPAs     0   $ 6,000,000.0
Affitech | Commercial Payment Purchase Agreement | Sales-based milestones, third          
Agreements          
Contingent consideration under RPAs, AAAs and CPPAs     3,000,000.0    
Short-term royalty and commercial payment receivables     $ 3,000,000.0